Small-Cell Lung Cancer - Pipeline Review, H1 2018

  • ID: 4542995
  • Drug Pipelines
  • 810 pages
  • Global Markets Direct
1 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Bavarian Nordic A/S
  • Cytori Therapeutics Inc
  • Johnson & Johnson
  • Nippon Kayaku Co Ltd
  • Syros Pharmaceuticals Inc
  • MORE
Small-Cell Lung Cancer - Pipeline Review, H1 2018

Summary:

This latest Pharmaceutical and Healthcare disease pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2018, provides an overview of the Small-Cell Lung Cancer (Oncology) pipeline landscape.

Small cell lung cancer (SCLC) is a fast-growing type of lung cancer. It spreads much more quickly than non-small cell lung cancer. SCLC is the most aggressive form of lung cancer. It usually starts in the breathing tubes (bronchi) in the center of the chest. These tumors often spread rapidly (metastasize) to other parts of the body, including the brain, liver, and bone. Symptoms of SCLC include bloody sputum, chest pain, cough, loss of appetite, weight loss and wheezing. Treatment includes surgery, radiation therapy and chemotherapy.

Report Highlights:

This latest pipeline guide Small-Cell Lung Cancer - Pipeline Review, H1 2018, provides comprehensive information on the therapeutics under development for Small-Cell Lung Cancer (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Small-Cell Lung Cancer (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Small-Cell Lung Cancer and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical and Discovery stages are 1, 9, 47, 33, 2, 36 and 6 respectively. Similarly, the Universities portfolio in Phase II, Preclinical and Discovery stages comprises 2, 3 and 1 molecules, respectively.

Small-Cell Lung Cancer (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from the researcher's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope:
  • The pipeline guide provides a snapshot of the global therapeutic landscape of Small-Cell Lung Cancer (Oncology).
  • The pipeline guide reviews pipeline therapeutics for Small-Cell Lung Cancer (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
  • The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
  • The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
  • The pipeline guide reviews key companies involved in Small-Cell Lung Cancer (Oncology) therapeutics and enlists all their major and minor projects.
  • The pipeline guide evaluates Small-Cell Lung Cancer (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
  • The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
  • The pipeline guide reviews latest news related to pipeline therapeutics for Small-Cell Lung Cancer (Oncology)
Reasons to buy:
  • Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
  • Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
  • Find and recognize significant and varied types of therapeutics under development for Small-Cell Lung Cancer (Oncology).
  • Classify potential new clients or partners in the target demographic.
  • Develop tactical initiatives by understanding the focus areas of leading companies.
  • Plan mergers and acquisitions meritoriously by identifying key players and it’s most promising pipeline therapeutics.
  • Formulate corrective measures for pipeline projects by understanding Small-Cell Lung Cancer (Oncology) pipeline depth and focus of Indication therapeutics.
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
  • Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
READ MORE
Note: Product cover images may vary from those shown
2 of 4

FEATURED COMPANIES

  • AbbVie Inc
  • Bavarian Nordic A/S
  • Cytori Therapeutics Inc
  • Johnson & Johnson
  • Nippon Kayaku Co Ltd
  • Syros Pharmaceuticals Inc
  • MORE
Introduction

Small-Cell Lung Cancer - Overview

Small-Cell Lung Cancer - Therapeutics Development

Small-Cell Lung Cancer - Therapeutics Assessment

Small-Cell Lung Cancer - Companies Involved in Therapeutics Development

Small-Cell Lung Cancer - Drug Profiles

Small-Cell Lung Cancer - Dormant Projects

Small-Cell Lung Cancer - Discontinued Products

Small-Cell Lung Cancer - Product Development Milestones

Appendix

List of Tables

Number of Products under Development for Small-Cell Lung Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Products under Development by Companies, H1 2018

Products under Development by Universities/Institutes, H1 2018

Number of Products by Stage and Target, H1 2018

Number of Products by Stage and Mechanism of Action, H1 2018

Number of Products by Stage and Route of Administration, H1 2018

Number of Products by Stage and Molecule Type, H1 2018

Small-Cell Lung Cancer - Pipeline by AbbVie Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Advenchen Laboratories LLC, H1 2018

Small-Cell Lung Cancer - Pipeline by Aeglea BioTherapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Amgen Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Andarix Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Aposense Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Aprea AB, H1 2018

Small-Cell Lung Cancer - Pipeline by Ascentage Pharma Group Corp Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Astellas Pharma Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Astex Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by AstraZeneca Plc, H1 2018

Small-Cell Lung Cancer - Pipeline by Autolus Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by AVEO Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Bavarian Nordic A/S, H1 2018

Small-Cell Lung Cancer - Pipeline by Bayer AG, H1 2018

Small-Cell Lung Cancer - Pipeline by BeiGene Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Beta Pharma Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by BeyondSpring Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by BioLineRx Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Bionomics Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Bristol-Myers Squibb Co, H1 2018

Small-Cell Lung Cancer - Pipeline by Celgene Corp, H1 2018

Small-Cell Lung Cancer - Pipeline by Celldex Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Checkpoint Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Chipscreen Biosciences Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Cotinga Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Cytori Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Double Bond Pharmaceutical International AB, H1 2018

Small-Cell Lung Cancer - Pipeline by Eli Lilly and Co, H1 2018

Small-Cell Lung Cancer - Pipeline by F. Hoffmann-La Roche Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by G1 Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by GlaxoSmithKline Plc, H1 2018

Small-Cell Lung Cancer - Pipeline by Hanmi Pharmaceuticals Co Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Horizon Pharma Plc, H1 2018

Small-Cell Lung Cancer - Pipeline by Immunomedics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Incyte Corp, H1 2018

Small-Cell Lung Cancer - Pipeline by Ipsen SA, H1 2018

Small-Cell Lung Cancer - Pipeline by Jiangsu Hengrui Medicine Co Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Johnson & Johnson, H1 2018

Small-Cell Lung Cancer - Pipeline by Karyopharm Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by MabVax Therapeutics Holdings Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by MedImmune LLC, H1 2018

Small-Cell Lung Cancer - Pipeline by Merck & Co Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Merck KGaA, H1 2018

Small-Cell Lung Cancer - Pipeline by Merrimack Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Mirati Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Moderna Therapeutics Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Mologen AG, H1 2018

Small-Cell Lung Cancer - Pipeline by Nektar Therapeutics, H1 2018

Small-Cell Lung Cancer - Pipeline by NewLink Genetics Corp, H1 2018

Small-Cell Lung Cancer - Pipeline by Nippon Kayaku Co Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Novartis AG, H1 2018

Small-Cell Lung Cancer - Pipeline by Ono Pharmaceutical Co Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Oxford BioTherapeutics Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Pfizer Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Pharma Mar SA, H1 2018

Small-Cell Lung Cancer - Pipeline by Plexxikon Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Rafael Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Recombio SL, H1 2018

Small-Cell Lung Cancer - Pipeline by Rexahn Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Sierra Oncology Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Sun Pharma Advanced Research Company Ltd, H1 2018

Small-Cell Lung Cancer - Pipeline by Sunshine Biopharma Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Syros Pharmaceuticals Inc, H1 2018

Small-Cell Lung Cancer - Pipeline by Takeda Pharmaceutical Co Ltd, H1 2018

List of Figures

Number of Products under Development for Small-Cell Lung Cancer, H1 2018

Number of Products under Development by Companies, H1 2018

Number of Products under Development by Universities/Institutes, H1 2018

Number of Products by Top 10 Targets, H1 2018

Number of Products by Stage and Top 10 Targets, H1 2018

Number of Products by Top 10 Mechanism of Actions, H1 2018

Number of Products by Stage and Top 10 Mechanism of Actions, H1 2018

Number of Products by Routes of Administration, H1 2018

Number of Products by Stage and Routes of Administration, H1 2018

Number of Products by Top 10 Molecule Types, H1 2018

Number of Products by Stage and Top 10 Molecule Types, H1
Note: Product cover images may vary from those shown
3 of 4

Loading
LOADING...

4 of 4
  • AbbVie Inc
  • Advenchen Laboratories LLC
  • Aeglea BioTherapeutics Inc
  • Amgen Inc
  • Andarix Pharmaceuticals Inc
  • Aposense Ltd
  • Aprea AB
  • Ascentage Pharma Group Corp Ltd
  • Astellas Pharma Inc
  • Astex Pharmaceuticals Inc
  • AstraZeneca Plc
  • Autolus Ltd
  • AVEO Pharmaceuticals Inc
  • Bavarian Nordic A/S
  • Bayer AG
  • BeiGene Ltd
  • Beta Pharma Inc
  • BeyondSpring Pharmaceuticals Inc
  • BioLineRx Ltd
  • Bionomics Ltd
  • Bristol-Myers Squibb Co
  • Celgene Corp
  • Celldex Therapeutics Inc
  • Checkpoint Therapeutics Inc
  • Chipscreen Biosciences Ltd
  • Cotinga Pharmaceuticals Inc
  • Cytori Therapeutics Inc
  • Double Bond Pharmaceutical International AB
  • Eli Lilly and Co
  • F. Hoffmann-La Roche Ltd
  • G1 Therapeutics Inc
  • GlaxoSmithKline Plc
  • Hanmi Pharmaceuticals Co Ltd
  • Horizon Pharma Plc
  • Immunomedics Inc
  • Incyte Corp
  • Ipsen SA
  • Jiangsu Hengrui Medicine Co Ltd
  • Johnson & Johnson
  • Karyopharm Therapeutics Inc
  • MabVax Therapeutics Holdings Inc
  • MedImmune LLC
  • Merck & Co Inc
  • Merck KGaA
  • Merrimack Pharmaceuticals Inc
  • Mirati Therapeutics Inc
  • Moderna Therapeutics Inc
  • Mologen AG
  • Nektar Therapeutics
  • NewLink Genetics Corp
  • Nippon Kayaku Co Ltd
  • Novartis AG
  • Ono Pharmaceutical Co Ltd
  • Oxford BioTherapeutics Ltd
  • Pfizer Inc
  • Pharma Mar SA
  • Plexxikon Inc
  • Rafael Pharmaceuticals Inc
  • Recombio SL
  • Rexahn Pharmaceuticals Inc
  • Sierra Oncology Inc
  • Sun Pharma Advanced Research Company Ltd
  • Sunshine Biopharma Inc
  • Syros Pharmaceuticals Inc
  • Takeda Pharmaceutical Co Ltd
  • Tarveda Therapeutics Inc
  • Tesaro Inc
  • Teva Pharmaceutical Industries Ltd
  • Trillium Therapeutics Inc
  • Trovagene Inc
  • United Therapeutics Corp
  • Verastem Inc
  • Xencor Inc
  • Zensun (Shanghai) Sci & Tech Co Ltd
  • ZIOPHARM Oncology Inc
Note: Product cover images may vary from those shown
5 of 4
Note: Product cover images may vary from those shown
Adroll
adroll